摘要
高脂血症是临床常见病和多发病，目前治疗以药物为主。ＨＭＧＣｏＡ还原酶抑制剂是近年来上市的一类新型的调血脂药物，由于这类药物针对病因，疗效显著，药物不良反应少，耐受性好，而受到广泛的重视和好评。作为最新人工合成的ＨＭＧＣｏＡ还原酶抑制剂的氟伐他汀，在药代和药效学方面都有一定的特点，不良反应比较少，疗效肯定。
Hypercholesterolemia is a global disease which has high morbility. Drug treatment is the most important method to hypercholesterolemia. HMG-CoA reductase inhibitor is a new anti-hypercholesterolemia agent which is widely used in clinical treatment. Because it effectively resists the cause of the disease, and has high efficacy with little side effect, and also has good tolerance, the drugs got good reputation and become a major focus all over the world. As a new completely synthetic HMG-CoA reductase inhibitor, Fluvastatin has many advantages in biopharmaceutics and pharmacodynamics, achieving significant results in treatment with few adverse effects. It has been considered as a promising drug in the treatment of hypercholesterolemia.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
1999年第2期141-148,共8页
The Chinese Journal of Clinical Pharmacology
